Align TechnologyALGN
About: Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.
Employees: 21,200
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
50% more funds holding in top 10
Funds holding in top 10: 4 [Q4 2024] → 6 (+2) [Q1 2025]
11% more repeat investments, than reductions
Existing positions increased: 260 | Existing positions reduced: 234
1.21% more ownership
Funds ownership: 87.52% [Q4 2024] → 88.73% (+1.21%) [Q1 2025]
4% less funds holding
Funds holding: 705 [Q4 2024] → 674 (-31) [Q1 2025]
15% less first-time investments, than exits
New positions opened: 93 | Existing positions closed: 110
24% less capital invested
Capital invested by funds: $13.6B [Q4 2024] → $10.4B (-$3.26B) [Q1 2025]
48% less call options, than puts
Call options by funds: $148M | Put options by funds: $286M
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
Evercore ISI Group | 8%upside $220 | Outperform Maintained | 9 Jul 2025 |
Wells Fargo Vik Chopra | 21%upside $246 | Overweight Maintained | 1 May 2025 |
Piper Sandler Jason Bednar | 23%upside $250 | Overweight Reiterated | 1 May 2025 |
Evercore ISI Group Elizabeth Anderson | 2%downside $200 | Outperform Maintained | 1 May 2025 |
Financial journalist opinion
Based on 16 articles about ALGN published over the past 30 days
